Irinotecan Hikma (Irinotecan Hydrochloride Trihydrate)

After infusion, irinotecan is metabolised to SN‑38, which binds to DNA‑topoisomerase I. This prevents the enzyme from resealing single‑strand DNA breaks that occur during replication, leading to accumulation of DNA damage and ultimately causing tumor cell death.

The dose of Irinotecan Hikma is individualized by the prescribing oncologist based on factors such as cancer type, treatment regimen, patient weight, liver function and prior therapy. Clinicians determine the exact amount, infusion rate and schedule for each patient.

Safety data for Irinotecan in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and breastfeeding is generally discouraged during treatment.

To order, submit an enquiry on the Irinotecan Hikma product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Irinotecan and topotecan are the two main topoisomerase I inhibitors. Irinotecan is typically used for colorectal cancers and is administered intravenously, whereas topotecan is often used for ovarian and small‑cell lung cancers and can be given intravenously or orally. Irinotecan’s active metabolite SN‑38 has a longer half‑life, which may affect toxicity profiles.

Irinotecan Hikma should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original container until use and handled in accordance with aseptic technique to maintain sterility.

Irinotecan Hikma is given as an intravenous infusion, usually over 30‑90 minutes depending on the protocol. The infusion is performed by qualified healthcare professionals in a clinical setting, with appropriate monitoring of vital signs and supportive care for potential side effects.

The most serious risks include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea that can lead to dehydration or colitis, hepatic toxicity, and rare but severe infusion‑related allergic reactions. Prompt medical attention is required if any of these occur.

Irinotecan Hikma is contraindicated in patients with known hypersensitivity to irinotecan or any of its excipients, those with severe bone‑marrow suppression, uncontrolled infections, or significant bowel obstruction. Caution is also advised for patients with impaired hepatic function or known UGT1A1 deficiency.